Amylyx Pharmaceuticals Nominates New Candidate AMX0318 for Rare Diseases
Amylyx Pharmaceuticals announced AMX0318, a novel GLP-1 receptor antagonist developed with Gubra A/S, targeting post-bariatric hypoglycemia. IND-enabling studies are planned for 2026.